Yes, you can get gout in the heel of your foot, but it is an uncommon location. Roughly 3% to 10% of people with gout develop hindfoot involvement, and an attack confined to the heel alone is rarer still. Crystals of monosodium urate settle in the Achilles insertion, the retrocalcaneal bursa, the plantar fascia origin, or the calcaneus itself. The result is a hot, swollen heel that hurts at rest and cannot bear weight, and it is regularly mistaken for plantar fasciitis or Achilles tendinopathy. Confirmation needs urate testing or imaging, not the address of the pain.
Causes: Why Urate Crystals Land in the Heel
Gout begins with a solubility problem, not a dietary one. Uric acid saturates blood at about 6.8 mg/dL at body temperature, and above that line the risk of crystallization climbs steeply. Serum urate of 7.0 mg/dL produces a small but real chance of a first flare; 9.0 mg/dL produces roughly a 20-fold higher annual risk. Urate is the end product of purine breakdown, and humans lack the enzyme that other mammals use to dismantle it.
Crystals favor tissue that is cool, slightly acidic, mechanically stressed, and poorly supplied with blood. The heel checks every box. The Achilles insertion and the plantar fascia origin are fibrocartilaginous entheses with sparse vasculature. Skin over the posterior heel runs several degrees cooler than the core. Repetitive loading from walking creates microtrauma that seeds deposition. The retrocalcaneal bursa is synovial-lined, which makes it behave much like a small joint.
Once crystals form, the pain is generated by the immune system rather than by the crystal mass. Macrophages recognize urate crystals as a danger signal, assemble the NLRP3 inflammasome, and release interleukin-1 beta. That cytokine cascade produces the heat, swelling, and exquisite tenderness within hours. In plain terms: a gram of crystal can trigger an immune reaction far out of proportion to its size.
There is a structural twist specific to the heel. Gout can attack the calcaneus directly, causing punched-out erosions with overhanging edges on imaging. It can also inflame the subtalar joint, which produces hindfoot pain on uneven ground rather than classic big-toe pain. Both patterns are easy to attribute to wear and tear, especially in someone over 60.
Can You Get Gout in the Heel of Your Foot? Prevalence in Numbers
Gout affects about 3.9% of American adults, roughly 9.2 million people, according to CDC analysis of 2015-2016 national survey data. Incidence runs about 1 to 2 new cases per 1,000 person-years, and it rises with age, kidney disease, and diuretic use. The classic site, the first metatarsophalangeal joint, accounts for at least half of first attacks.
The heel sits far down that list. Pooled clinical and imaging series put hindfoot involvement at roughly 3% to 10% of patients with gout. A heel flare as the very first symptom is uncommon, and isolated calcaneal gout is mostly reported as small case series. In one sense that rarity is the headline: heel pain is common, heel gout is not.
Here is a comparison that reframes the odds. Of 1,000 adults who walk into a clinic with heel pain, roughly 800 have plantar fasciitis, and most of the rest have Achilles tendinopathy, bursitis, a stress fracture, or nerve entrapment. Fewer than 10 will have gout as the explanation. The prior probability matters, and it shifts the diagnostic workup.
The picture changes in people who already have a gout diagnosis. Ultrasound and dual-energy CT studies of established gout find urate deposits in the Achilles tendon in roughly one-third of patients, and most of those people have no heel symptoms at all. Subclinical crystal deposition is common; symptomatic heel flares are the minority outcome. A heel that hurts in a known gout patient therefore deserves more suspicion than the same heel in someone with no urate history.
Risk concentrates in a specific profile: men over 40, postmenopausal women, anyone with an eGFR below 60, thiazide or loop diuretic users, and people with a history of tophi. In those groups, hindfoot gout is both more likely and more often missed.
Heel Gout vs Other Heel Pain: Comparison Table
| Feature | Heel gout | Plantar fasciitis | Insertional Achilles tendinopathy | Calcaneal stress fracture |
|---|---|---|---|---|
| Typical onset | Overnight, peak in 8 to 24 hours | Gradual over weeks | Gradual over weeks to months | Gradual, tied to training load |
| Worst moment | 2 a.m. to 6 a.m., even at rest | First steps out of bed | After running or stairs | With every weight-bearing step |
| Swelling and color | Warm, red, shiny skin in most attacks | Minimal or none | Focal thickening, no redness | Mild diffuse swelling |
| Blood work | CRP often above 10 mg/L; urate may be normal | Normal | Normal | Normal or mildly raised |
| Imaging signature | Double-contour sign, tophi, erosions | Heel spur in about half, but also in a quarter of pain-free adults | Tendon thickening above 6 mm with neovascularization | Marrow edema on MRI |
| Response in 48 to 72 hours | Dramatic to NSAIDs, colchicine, or steroids | Slow, responds to loading changes | Slow, responds to a loading program | Slow, needs offloading |
The practical read: a heel that turns red and hot overnight, hurts under a bedsheet, and improves sharply with an anti-inflammatory is behaving like gout. A heel that hurts most on the first step of the morning and never swells is behaving like a mechanical problem.
Timeline of a Heel Gout Flare
| Time from first symptom | What happens | What it means |
|---|---|---|
| 0 to 12 hours | Tingling or stiffness behind the heel, then rapid escalation | The treatable window opens here |
| 12 to 36 hours | Pain peaks; skin becomes taut, red, and hot; CRP climbs | Peak intensity arrives fast, usually within a day |
| Day 2 to 3 | Swelling plateaus; weight-bearing becomes difficult | Fluid and immune cells accumulate in bursa and soft tissue |
| Day 3 to 7 | Pain declines; skin may peel and itch | Crystal clearance begins; most untreated attacks still hurt |
| Day 7 to 14 | About 7 in 10 untreated attacks resolve completely | Resolution is the natural history, not proof of another diagnosis |
| Week 2 to 4 | Residual stiffness, especially on stretching the calf | Soft tissue inflammation outlasts the pain |
| Week 4 onward | Intercritical period; crystals remain in the tissue | Roughly 60% of untreated people have a second attack within a year |
Two numbers need reconciling here, because they get quoted against each other. Untreated gout attacks usually last 3 to 10 days, but severe polyarticular or bursal attacks can run 3 weeks. Both are true: the 3-to-10-day figure describes a typical single-joint flare, while the longer range describes extensive or undertreated disease. A heel attack that is still red at day 21 is not automatically something else, but it does justify aspiration.
Why Heel Gout Is Missed or Misdiagnosed
The single biggest trap is the serum urate drawn during the flare. Urate falls by roughly 0.5 to 2.0 mg/dL during an acute attack because of the inflammatory response and increased renal excretion. Up to a third of people with proven gout have a normal urate level at the moment they are in the office with a hot heel. A normal result during a flare does not exclude gout; the level needs repeating two weeks after the attack settles.
The second trap is the heel spur. Radiographic plantar spurs appear in roughly a quarter of adults with no heel pain and in about half of those with plantar fasciitis. Finding one explains nothing. Gout erosions look different: punched-out lesions with sclerotic margins and overhanging edges, usually at the enthesis or within the calcaneal body.
The third trap is the spondyloarthritis overlap. Both conditions inflame entheses, both cause morning stiffness, and both can raise CRP. The distinguishing features are the crystal finding on aspiration and the distribution of other joint involvement. Ankylosing spondylitis tends to bring inflammatory back pain and bilateral heel pain in a younger adult; heel gout tends to arrive asymmetrically in an older adult with kidney disease or diuretic exposure.
The fourth trap is imaging overreach. The ultrasound double-contour sign is highly specific for urate deposition, but it can persist for months after urate levels normalize, so it cannot be used to judge flare activity. Dual-energy CT can miss small or low-density deposits and is unreliable in feet with heavy artifact from prior surgery. A negative scan lowers probability; it does not close the case.
What the evidence cannot tell you is precise incidence. There is no large population cohort dedicated to heel gout, so the 3% to 10% hindfoot figure is assembled from imaging studies, rheumatology clinic series, and case reports. Treat those ranges as informed estimates rather than measured constants.
Red Flags That Point Away From Gout
- Fever of 38.3°C (101°F) or higher, chills, or feeling systemically ill with a hot heel.
- Inability to bear weight combined with a rapidly worsening joint over 6 to 12 hours.
- Skin breakdown, an open wound, or a diabetic foot ulcer near the painful area.
- Recent joint injection, foot surgery, or immunosuppressive therapy.
- Heel pain with calf swelling, calf tenderness, or unilateral leg edema.
- Pain that continues to escalate beyond 72 hours despite adequate anti-inflammatory treatment.
These features raise the probability of septic arthritis, osteomyelitis, or deep vein thrombosis. Septic arthritis in a small foot joint carries meaningful mortality and destroys cartilage within days, so a swollen hot heel with fever needs aspiration and cultures, not a trial of colchicine.
What to Actually Do
Start with timing. If the heel went from normal to unbearable in under 24 hours, get evaluated the same week and ask specifically about crystal arthritis. If the pain crept in over a month, mechanical causes lead the list, but ask for a serum urate anyway as a baseline.
The definitive test is arthrocentesis. A needle into the retrocalcaneal bursa or the symptomatic joint yields fluid that, under polarized light, shows needle-shaped crystals that are yellow when parallel to the compensator and blue when perpendicular, meaning negatively birefringent. That single finding separates gout from every mimic. When aspiration is not feasible, ultrasound looking for the double-contour sign and tophi is the next best step.
Acute treatment follows the 2020 American College of Rheumatology guideline: an NSAID at full anti-inflammatory dose, colchicine started within 36 hours of onset, or a short course of oral glucocorticoids, with the choice driven by kidney function and comorbidities. Do not stop an existing urate-lowering drug during a flare. Combine low-dose colchicine with the anti-inflammatory if a single agent is not enough.
Long-term treatment is where the heel stops recurring. Urate-lowering therapy is indicated for two or more flares a year, any tophus, kidney disease stage 3 or worse, or a history of kidney stones. Allopurinol starts at 100 mg daily, or 50 mg in advanced kidney disease, and is titrated every 2 to 4 weeks. These thresholds are not competing numbers: 6.8 mg/dL is the saturation point where crystals form, while the targets of 6.0 mg/dL and 5.0 mg/dL sit deliberately below saturation so existing deposits dissolve.
Practical numbers to hold on to: about 70% of people reach target on allopurinol alone at doses between 200 and 400 mg daily, and screening for HLA-B*5801 before starting is advised in Han Chinese, Korean, and Thai patients because of severe hypersensitivity risk. Thiazide and loop diuretics raise urate and should be swapped where a clinical equivalent exists. Beer and sugar-sweetened beverages carry more risk per serving than purine-rich vegetables, a correction to older diet advice.
Finally, treat the heel mechanically while the chemistry is corrected. Cushioned heel cups, a temporary rocker-sole shoe, and avoiding barefoot walking reduce load through an inflamed bursa. They control symptoms; they do not lower urate. Recheck urate and kidney function three months after any dose change, because a heel that flared once at 8.2 mg/dL will flare again unless the number moves.